NCT05393466View on ClinicalTrials.gov

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2026

Primary Completion Date

January 30, 2028

Study Completion Date

May 31, 2029

Conditions
Non-small Cell Lung Carcinoma
Interventions
DRUG

BPI-361175

BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.

All Listed Sponsors
lead

Xcovery Holdings, Inc.

INDUSTRY

NCT05393466 - BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter